Pharmacokinetics and Pharmacodynamics of Twice-Yearly Depemokimab in the Randomized, Double-Blind, Placebo-Controlled Parallel Phase III ANCHOR-1/2 Trials 🔗 Access full article via Journal of Allergy and Clinical ImmunologyShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
